Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or
capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet
[Internet]. 2019
Perioperative Chemotherapy
• Periode perioperatif ini mungkin hanya 1 atau 2 hari dalam satu kasus, atau
beberapa minggu atau bahkan beberapa bulan dalam kasus lain
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or
capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019
REGIMEN KEMOTERAPI PERIOPERATIVE
• Regimen yang biasa digunakan dalam kemoterapi perioperative antara lain sebagai
berikut
1. Epirubicin, cisplatin, dan fluorouracil ( ECF) diberikan sebelum dan
sesudah operasi untuk obat lini pertama
2. Docetaxel, cisplatin, dan fluorouracil [DCF] diberikan setiap 3
minggu untuk obat lini ke 2 akan tetapi toksisitas tinggi
3. Fluorouracil, leucovorin, oxaliplatin, dan docetaxel (FLOT) untuk
obat lini pertama atau kedua akan tetapi toksisitas lebih rendah dan
aman digunakan
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or
capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019
Perbandingan Overall Survival dan Disease Free Survival pada
Regimen ECF dan FLOT
Ardhiansyah, AO.2018.
Toksisitas
Sanford, R. A. et al. (2016) ‘Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients’, Annals of
Surgical Oncology, 23(5), pp. 1515–1521.
Perioperative Chemotherapy Guideline
Recomendation
• Rekomendasi:
Kemoterapi perioperatif (pra dan pasca operasi) dengan kombinasi
platinum / fluoropyrimidine direkomendasikan untuk pasien dengan
≥ Stadium IB kanker lambung yang dapat dioperasi
[I, A]
• Perbaikan 5 year survival 23% - 36% pada pasien dengan kanker lambung
stadium II dan III resektabel yang diobati dengan enam siklus (tiga pre dan
tiga pasca operasi) kemoterapi ECF perioperative
• Perbaikan 5 year survival 23% - 36% pada pasien dengan kanker lambung
stadium II dan III resektabel yang diberi regimen cisplatin dan 5-FU 28 hari
perioperatif
• Durasi pengobatan yang disarankan adalah 2-3 bulan.
Gastric cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up
TINJAUAN PUSTAKA
• Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative
chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or
capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-
oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet [Internet].
2019;393(10184):1948–57. Available from: http://dx.doi.org/10.1016/S0140-6736(18)32557-1
• Brehler ACE, Hartmann W, Wiebe S, Kerkhoff A, Schliemann C, Palmes D, et al. Perioperative
chemotherapy in gastroesophageal cancer. A retrospective monocenter evaluation of 42 cases.
PLoS One. 2015;10(4):1–11.
• Ardhiansyah, AO.2018. Kanker Kolorektal. Airlangga University Press.
• Grenon and Chan, 2019. Managing Toxicities Associated with Colorectal Chemotheraphy and
Targeted Therapy. Clinical Journal of Oncology Nursing.
• Cutsem, Eric Van, 2010. ESMO Guidelines: ESMO Clinical Practice Guidelines for Treatment.
• Sanford, R. A. et al. (2016) ‘Impact of Time from Completion of Neoadjuvant Chemotherapy to
Surgery on Survival Outcomes in Breast Cancer Patients’, Annals of Surgical Oncology, 23(5), pp.
1515–1521.